BRPI0416355A - métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss - Google Patents

métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss

Info

Publication number
BRPI0416355A
BRPI0416355A BRPI0416355-9A BRPI0416355A BRPI0416355A BR PI0416355 A BRPI0416355 A BR PI0416355A BR PI0416355 A BRPI0416355 A BR PI0416355A BR PI0416355 A BRPI0416355 A BR PI0416355A
Authority
BR
Brazil
Prior art keywords
sjs
hla
developing
drug
patient
Prior art date
Application number
BRPI0416355-9A
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Shuen-Iu Hung
Wen-Hung Chung
Jer-Yuarn Wu
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34552314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416355(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of BRPI0416355A publication Critical patent/BRPI0416355A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODOS PARA AVALIAR O RISCO DE UM PACIENTE DESENVOLVER UMA REAçãO ADVERSA A DROGA, PARA DESENVOLVER UMA TERAPIA PARA UMA REAçãO ADVERSA INDUZIDA POR UMA DROGA, PARA AVALIAR O RISCO DE UM PACIENTE DESENVOLVER SJS, TEN OU HSS, E PARA IDENTIFICAR UMA DROGA QUE INDUZ SJS, TEN OU HSS". A presente invenção provê um método de predizer o risco de um paciente desenvolver reações adversas a droga, particularmente a síndrome Stevens-Johnson (SJS), necrólise epidérmica tóxica (TEN) ou síndrome de hipersensibilidade a droga (HSS). Descobriu-se que um alelo HLA-13, HLA-B* 1502 associado com SJS/TEN, que são induzidos por uma variedade de drogas. A correlação com HLA-B* 1502 é muitíssimo significativa para SJS/TEN induzidos por carbamazepina, em que todos os pacientes testados têm o alelo HLA-13*1502. Além disso, outro alelo HLA13, HLA-B*5801, é particularmente associado com SJS/TEN ou HSS induzidos por alopurinol. Reações cutâneas mais suaves, tais como erupção maculopapular, eritema multiforme (EM), urticária e erupção por droga fixa, são particularmente associadas com um terceiro alelo, HLA-13*4601. Para qualquer um dos alelos, os marcadores genéticos (p. ex., marcadores HLA, microssatélite ou marcadores de polimorfismo de nucleotídeo simples), localizados entre a região DRB1 e HLA-A do haplótipo HLA-B específico, podem também ser usados para o teste.
BRPI0416355-9A 2003-11-10 2004-06-18 métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss BRPI0416355A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/705,245 US7470513B2 (en) 2003-11-10 2003-11-10 Risk assessment for adverse drug reactions
PCT/US2004/019435 WO2005047544A1 (en) 2003-11-10 2004-06-18 Risk assessment for adverse drug reactions

Publications (1)

Publication Number Publication Date
BRPI0416355A true BRPI0416355A (pt) 2007-03-13

Family

ID=34552314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416355-9A BRPI0416355A (pt) 2003-11-10 2004-06-18 métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss

Country Status (16)

Country Link
US (5) US7470513B2 (pt)
EP (1) EP1697539B1 (pt)
CN (1) CN1902328B (pt)
AT (1) ATE476524T1 (pt)
AU (1) AU2004289951B2 (pt)
BR (1) BRPI0416355A (pt)
CA (1) CA2544369C (pt)
CY (1) CY1110760T1 (pt)
DE (1) DE602004028508D1 (pt)
DK (1) DK1697539T3 (pt)
ES (1) ES2347150T3 (pt)
PL (1) PL1697539T3 (pt)
PT (1) PT1697539E (pt)
SI (1) SI1697539T1 (pt)
TW (1) TWI287580B (pt)
WO (1) WO2005047544A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20060166224A1 (en) * 2005-01-24 2006-07-27 Norviel Vernon A Associations using genotypes and phenotypes
US7452689B2 (en) * 2005-05-20 2008-11-18 Mayo Foundation For Medical Education And Research Method for rapid determination of thiopurine methyltransferase activity
PT2016198E (pt) * 2006-05-11 2013-07-29 Academia Sinica Método para a predição de um risco de reacções adversas a fármacos por meio da determinação de hla-b 1502
DK2344892T3 (da) * 2008-10-01 2014-08-18 Univ Arizona State Glucuronideret paracetamol som markør for hepatiske lidelser
CN102108382A (zh) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 卡马西平致皮肤严重不良反应遗传检测
WO2011130152A2 (en) * 2010-04-12 2011-10-20 Academia Sinica Method for identifying hla complexes associated with adverse drug reactions
JP5959634B2 (ja) * 2011-06-23 2016-08-02 チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン フェニトインによって誘発される薬の副作用のリスク評価
CN105039579B (zh) * 2011-06-23 2018-10-02 长庚医疗财团法人基隆长庚纪念医院 用hla等位基因评估抗癫痫药物苯妥英引发药物过敏反应的方法
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
TW201307846A (zh) * 2011-08-02 2013-02-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung 評估抗癲癇藥物引發不良反應或過敏反應風險（ａｄｒ）的方法
US10370409B2 (en) 2011-10-25 2019-08-06 The Scripps Research Institute Synthesis of libraries of peptide tertiary amides
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102925567B (zh) * 2012-10-23 2013-12-11 山东省皮肤病性病防治研究所 Hla-b*1301等位基因的用途
CA2894511C (en) 2012-12-11 2021-12-07 Albert Einstein College Of Medicine Of Yeshiva University Methods for high throughput receptor:ligand identification
JP2015107095A (ja) * 2013-03-14 2015-06-11 凸版印刷株式会社 眼合併症を伴う重症薬疹の発症リスクの評価方法
CN104818316B (zh) * 2013-11-28 2018-09-21 复旦大学 用于筛查柳氮磺胺吡啶所致皮肤药物不良反应的人类白细胞抗原基因检测试剂盒
CN103646185A (zh) * 2013-12-25 2014-03-19 顾德国 一种药品不良反应报告质量评估系统及方法
CN104017898B (zh) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
KR101591603B1 (ko) * 2014-10-16 2016-02-04 연세대학교 산학협력단 약물유해반응 예측에 관한 정보 제공 방법
CN104450914A (zh) * 2014-12-10 2015-03-25 苏州旷远生物分子技术有限公司 用于检测人hla-b*1502基因的引物、探针、荧光pcr试剂盒和方法
US9927443B2 (en) 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
US9932638B2 (en) 2015-06-29 2018-04-03 Millennium Health, LLC Single nucleotide polymorphism in HLA-B*15:02 and use thereof
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP6395061B2 (ja) * 2016-06-21 2018-09-26 チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン フェニトインによって誘発される薬の副作用のリスクを評価する方法
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
US11289178B2 (en) 2017-04-21 2022-03-29 International Business Machines Corporation Identifying chemical substructures associated with adverse drug reactions
SG11202003391XA (en) * 2017-10-27 2020-05-28 Chang Gung Memorial Hospital Linkou Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
CN108342457B (zh) * 2018-04-01 2021-12-07 广东辉锦创兴生物医学科技有限公司 Hla-b5801等位基因的检测试剂盒及其应用
CN108866007A (zh) * 2018-04-26 2018-11-23 厦门敖依生物科技有限公司 一种检测hla-b*5801的单克隆抗体及其制备方法与应用
US20220177968A1 (en) * 2019-03-12 2022-06-09 Chang Gung Memorial Hospital, Linkou Methods for detecting or reducing the incidence of adverse drug reactions
SG11202111473UA (en) * 2019-05-06 2021-11-29 Chang Gung Memorial Hospital Linkou Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
US11763946B2 (en) * 2020-02-27 2023-09-19 Optum, Inc. Graph-based predictive inference
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
KR102650359B1 (ko) * 2021-08-13 2024-03-25 재단법인 아산사회복지재단 약물 과민반응 진단용 snp 및 이를 이용한 진단 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550039A (en) * 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Also Published As

Publication number Publication date
AU2004289951A1 (en) 2005-05-26
US20130330724A1 (en) 2013-12-12
PL1697539T3 (pl) 2010-12-31
US20050100926A1 (en) 2005-05-12
SI1697539T1 (sl) 2010-11-30
US7964351B2 (en) 2011-06-21
TW200525038A (en) 2005-08-01
CA2544369C (en) 2014-08-05
US8012686B2 (en) 2011-09-06
CY1110760T1 (el) 2015-06-10
ATE476524T1 (de) 2010-08-15
WO2005047544A1 (en) 2005-05-26
AU2004289951B2 (en) 2009-10-22
TWI287580B (en) 2007-10-01
ES2347150T3 (es) 2010-10-26
US20080227109A1 (en) 2008-09-18
CN1902328B (zh) 2010-10-20
US20090053727A1 (en) 2009-02-26
EP1697539A1 (en) 2006-09-06
CN1902328A (zh) 2007-01-24
CA2544369A1 (en) 2005-05-26
DK1697539T3 (da) 2010-11-22
US9562268B2 (en) 2017-02-07
PT1697539E (pt) 2010-10-04
DE602004028508D1 (de) 2010-09-16
EP1697539B1 (en) 2010-08-04
US7470513B2 (en) 2008-12-30
US20120077192A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
BRPI0416355A (pt) métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss
Vijai et al. A genome-wide association study of marginal zone lymphoma shows association to the HLA region
BRPI0710436A8 (pt) método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga
Friemel et al. Array-based DNA methylation profiling in male infertility reveals allele-specific DNA methylation in PIWIL1 and PIWIL2
He et al. Association between the HLA-B* 15: 02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China
BR0308161A (pt) métodos para a detecção de distúrbios genéticos
Reynolds et al. HLA–DRB1–associated rheumatoid arthritis risk at multiple levels in African Americans: hierarchical classification systems, amino acid positions, and residues
Becker et al. Evidence for differences in DNA methylation between Germans and Japanese
Jahantigh et al. Genetic polymorphisms and haplotypes of the DJ-1 gene promoter associated with the susceptibility to male infertility
JP5899527B2 (ja) 第６染色体短腕２１．３３領域の一塩基多型に基づく抗てんかん薬による薬疹リスクの検査方法
Moore et al. Sequence-based HLA-a, b, c, DP, DQ, and DR typing of 496 adults from San Diego, California, USA
Periñán et al. The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset
Tunca et al. Association of human leukocyte antigen class II alleles with pemphigus vulgaris in a Turkish population
Zajacova et al. Differences in promoter DNA methylation and mRNA expression of individual alleles of the HLA class II DQA1 gene
Jin et al. A novel mutation (c. 1010G> T; p. R337L) in TP63 as a cause of split‐hand/foot malformation with hypodontia
Correa et al. HLA‐DR and DQB1 gene polymorphism in the North‐western Colombian population
Given et al. The androgen receptor exon 1 trinucleotide repeat does not act as a modifier of the age of presentation in breast cancer
BRPI0510691A (pt) marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento
Zarrabeitia et al. X-linked microsatellites in two Northern Spain populations
Giegling et al. Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits
Yang et al. Genome-wide DNA methylation analysis of the regenerative and non-regenerative tissues in sika deer (Cervus nippon)
Calvo‐Ferrer et al. Identification of a novel HLA‐C* 07 allele, HLA‐C* 07: 943, in a Spanish individual.
Chen et al. The novel HLA‐DQB1* 03: 282N allele was identified in a Chinese individual.
Tsai et al. 68. GENOME-WIDE ASSOCIATION ANALYSIS OF AN IN SILICO PHENOTYPE SOURCED FROM CLINICAL NOTES: THE ADDICTION BEHAVIOR CHECKLIST
Quan et al. Characterization of the novel HLA‐DQB1* 03: 362 allele in a Chinese family.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2311 DE 22-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.